Publications by authors named "S Halimeh"
Background: The SIPPET randomized clinical trial showed that in previously untreated patients (PUPs) with severe hemophilia A, treatment with plasma-derived factor (F)VIII (pdFVIII) within the first 50 exposure days (EDs) was associated with a lower cumulative incidence of inhibitors than with recombinant FVIII (rFVIII). Switching to rFVIII beyond 50 EDs with pdFVIII is a treatment often implemented by many centers. The question is whether or not this switch may induce a risk of inhibitor development.
View Article and Find Full Text PDFSince the 1970s, specialized hemophilia centers have been established to optimize the complex and costly treatment of patients with severe bleeding disorders. In 2019, the first GTH guidelines on the structural and process quality of hemophilia centers were published. On this basis, a procedure for the certification of hemophilia centers has been established under the technical leadership of the GTH.
View Article and Find Full Text PDFBackground: Von Willebrand disease (VWD), the most prevalent hereditary bleeding disorder, results from deficiency of von Willebrand factor (VWF).
Objectives: This large cohort study aims to offer a comprehensive exploration of mutation spectra and laboratory features in quantitative VWF deficiencies, shedding light on genetic underpinnings and genotype-phenotype associations.
Methods: Our cohort consisted of 221 Caucasian index patients with quantitative VWD, along with 47 individuals whose plasma VWF levels fell within the lower normal boundaries (50-70 IU/dL).
Choosing a medical specialty is a critical decision that significantly impacts medical students' future career. Understanding the factors influencing this decision-making process is important for medical educators, policymakers, and healthcare providers to develop effective strategies that support and guide students in making informed decisions. We distributed an online self-administered questionnaire to clinical-year medical students (Years 4 to 6) and interns from all medical faculties in Jordan.
View Article and Find Full Text PDFArticle Synopsis
- - New guidelines on cerebral venous and dural sinus thrombosis (CVT) have emerged, focusing on risk factors, treatment options including direct oral anticoagulants, and interventional treatments, based on expert consensus from Germany, Austria, and Switzerland.
- - Key recommendations highlight that CVT may relate to severe thrombocytopenia post-SARS-CoV-2 vaccination, D-dimer testing is not advised for routine use, and thrombophilia screening should be considered under specific conditions.
- - Treatment recommendations suggest using low molecular weight heparin in the acute phase, with endovascular interventions for patients not responding adequately, and oral anticoagulation for 3 to 12 months afterward to reduce the risk of recurrence.